Obesity guidelines recommend multicomponent intensive lifestyle change programs in conjunction with GLP-1 medications; however, there is limited health system infrastructure for this recommended programming.<h4>Methods</h4>This was a single site, retrospective cohort study of patients who attended ≥1 virtual shared medical appointment (SMA) in a 4-part series on obesity and GLP-1 medications at the Massachusetts General Hospital (MGH) Healthy Lifestyle Program from October 2024 to September 2025. The gene discussed is GLP1R; the disease is obesity disorder.